COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression

Zhang,Longhui; Li,Sufen; Li,Lan; Chen,Zhengqiong; Yang,Ying

doi:10.3892/mmr.2017.8270

COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression

Authors:
- Longhui Zhang
- Sufen Li
- Lan Li
- Zhengqiong Chen
- Ying Yang
View Affiliations

Affiliations: Obstetrics and Gynecology Department, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China, Obstetrics and Gynecology Department, Chong Qing Health Center for Women and Children, Chongqing 400010, P.R. China
Published online on: December 12, 2017 https://doi.org/10.3892/mmr.2017.8270
Pages: 2937-2944
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous antitumor angiogenesis strategies have focused on targeting angiogenic signals. Encouragingly, the metabolism of tumor endothelial cells (TECs) has gained attention as a therapeutic target in recent years. There is consensus that, in terms of antitumor angiogenesis, the promotion of tumor vascular regression and normalization of the remaining blood vessels are equally important. Presently, tumor vessel normalization (TVN) is an emerging antitumor treatment. The present study focused on the normalization of TEC metabolism. The results demonstrated that TECs have a hyperglycolytic metabolism. Parixibox, a cyclooxygenase‑2 (COX‑2) blocker, successively reduces the expression of vascular endothelial growth factor (VEGF) in the tumor microenvironment. VEGF further influences the expression of 6‑Phosphofructo-2-Kinase/Fructose-2,6‑Biphosphatase 3, a key glycolysis gene. Pharmacological blockade of COX‑2 restored the glucose metabolism level (particularly glycolysis) in TECs, which may be an important basic process in TVN. Therefore, COX‑2, which acts on abnormal tumor vessels, is expected to become a novel target for tumor treatment.

View Figures

View References

1	Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
2	Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
3	Jain RK: Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell. 26:605–622. 2014. View Article : Google Scholar : PubMed/NCBI
4	Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P and Hämmerling GJ: Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 16:609–617. 2015. View Article : Google Scholar : PubMed/NCBI
5	Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, et al: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA. 113:pp. 4470–4475. 2016; View Article : Google Scholar : PubMed/NCBI
6	De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquière B, Cauwenberghs S, Eelen G, et al: Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 154:651–663. 2013. View Article : Google Scholar : PubMed/NCBI
7	Polet F and Feron O: Endothelial cell metabolism and tumour angiogenesis: Glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med. 273:156–165. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cruys B, Wong BW, Kuchnio A, Verdegem D, Cantelmo AR, Conradi LC, Vandekeere S, Bouché A, Cornelissen I, Vinckier S, et al: Glycolytic regulation of cell rearrangement in angiogenesis. Nat Commun. 7:122402016. View Article : Google Scholar : PubMed/NCBI
9	Xu Y, An X, Guo X, Habtetsion TG, Wang Y, Xu X, Kandala S, Li Q, Li H, Zhang C, et al: Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler Thromb Vasc Biol. 34:1231–1239. 2014. View Article : Google Scholar : PubMed/NCBI
10	Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, Chaturvedi P, Hol J, Thienpont B, Teuwen LA, et al: Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis and improves chemotherapy. Cancer Cell. 30:968–985. 2016. View Article : Google Scholar : PubMed/NCBI
11	De Bock K, Georgiadou M and Carmeliet P: Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 18:634–647. 2013. View Article : Google Scholar : PubMed/NCBI
12	Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, et al: Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 19:37–48. 2014. View Article : Google Scholar : PubMed/NCBI
13	Di Francesco L, Dovizio M, Trenti A, Marcantoni E, Moore A, O'Gaora P, McCarthy C, Tacconelli S, Bruno A, Alberti S, et al: Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells. Br J Pharmacol. Jul 3–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
14	Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:625–631. 2002.PubMed/NCBI
15	Sui W, Zhang Y, Wang Z, Wang Z, Jia Q, Wu L and Zhang W: Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model. Oncol Rep. 31:2252–2260. 2014. View Article : Google Scholar : PubMed/NCBI
16	Gaul C: Aspirin for migraine in pregnancy. This recommendation seems questionable. MMW Fortschr Med. 155:172013.(In German). View Article : Google Scholar : PubMed/NCBI
17	Salvado MD, Alfranca A, Haeggström JZ and Redondo JM: Prostanoids in tumor angiogenesis: Therapeutic intervention beyond COX-2. Trends Mol Med. 18:233–243. 2012. View Article : Google Scholar : PubMed/NCBI
18	Bijman MN, Hermelink CA, van Berkel MP, Laan AC, Janmaat ML, Peters GJ and Boven E: Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol. 75:427–437. 2008. View Article : Google Scholar : PubMed/NCBI
19	Di Francesco L, Totani L, Dovizio M, Piccoli A, Di Francesco A, Salvatore T, Pandolfi A, Evangelista V, Dercho RA, Seta F and Patrignani P: Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res. 104:506–513. 2009. View Article : Google Scholar : PubMed/NCBI
20	de Groot DJ, de Vries EG, Groen HJ and de Jong S: Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Crit Rev Oncol Hematol. 61:52–69. 2007. View Article : Google Scholar : PubMed/NCBI
21	Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S and Linton MF: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 39:443–452. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, Yoshimura H and Majima M: COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest. 83:1385–1394. 2003. View Article : Google Scholar : PubMed/NCBI
23	Wu G, Luo J, Rana JS, Laham R, Sellke FW and Li J: Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res. 69:512–519. 2006. View Article : Google Scholar : PubMed/NCBI
24	Vandekeere S, Dewerchin M and Carmeliet P: Angiogenesis revisited: An overlooked role of endothelial cell metabolism in vessel sprouting. Microcirculation. 22:509–517. 2015. View Article : Google Scholar : PubMed/NCBI
25	Goveia J, Stapor P and Carmeliet P: Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. EMBO Mol Med. 6:1105–1120. 2014. View Article : Google Scholar : PubMed/NCBI
26	Eelen G, de Zeeuw P, Simons M and Carmeliet P: Endothelial cell metabolism in normal and diseased vasculature. Circ Res. 116:1231–1244. 2015. View Article : Google Scholar : PubMed/NCBI
27	Sun CM, Xiong DB, Yan Y, Geng J, Liu M and Yao XD: Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer. Int J Biol Markers. 31:e286–e293. 2016. View Article : Google Scholar : PubMed/NCBI
28	Schoors S, Bruning U, Missiaen R, Queiroz KC, Borgers G, Elia I, Zecchin A, Cantelmo AR, Christen S, Goveia J, et al: Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature. 520:192–197. 2015. View Article : Google Scholar : PubMed/NCBI